- Remigromig showed non-inferiority to ranibizumab for mean change in best-corrected visual acuity at week 52.
Merck reported that remigromig met its primary endpoint, showing non-inferiority to ranibizumab for visual acuity improvement at 52 weeks. The data supports regulatory filing plans.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.